Alnylam Pharmaceuticals Prices Public Offering of Common Stock
May 24 2017 - 9:00AM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, today announced the pricing of an
underwritten public offering of 5,000,000 shares of its common
stock at a public offering price of $71.87 per share. The gross
proceeds to Alnylam from the offering, before deducting the
underwriting discounts and commissions and other estimated offering
expenses, are expected to be approximately $359.4 million. The
offering is expected to close on or about May 30, 2017,
subject to the satisfaction of customary closing conditions. In
addition, Alnylam has granted the underwriter of the offering a
30-day option to purchase up to an additional 750,000 shares of its
common stock solely to cover over-allotments. All of the shares in
the offering are to be sold by Alnylam.
Barclays Capital Inc. is acting as sole book-running manager for
the offering.
Alnylam intends to use the net proceeds from this offering for
general corporate purposes, including clinical trial costs and
other research and development expenses, continued growth of its
manufacturing, quality, commercial and medical affairs capabilities
to support its transition toward a commercial-stage
biopharmaceutical company, working capital, capital expenditures
and general and administrative expenses.
The securities described above are being offered by Alnylam
pursuant to an automatically effective shelf registration statement
that Alnylam previously filed with the Securities and Exchange
Commission (SEC).
A registration statement (including a base prospectus) relating
to these securities has been filed with the SEC and has become
effective. Before you invest, you should read these and other
documents Alnylam has filed with the SEC for more complete
information about Alnylam and this offering. You may get these
documents for free by visiting EDGAR on the SEC website at
www.sec.gov.
The offering will be made only by means of a preliminary
prospectus supplement and related prospectus. Copies of the
preliminary prospectus supplement and the final prospectus
supplement, when available, and the accompanying base prospectus
relating to the offering may be obtained by contacting Barclays
Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, New York 11717; barclaysprospectus@broadridge.com
(phone 888-603-5847).
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities nor shall there be
any sale of these securities in any state in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state.
About Alnylam PharmaceuticalsAlnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the
lives of patients who have limited or inadequate treatment options.
Based on Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically-validated approach for the treatment of a wide
range of debilitating diseases. Founded in 2002, Alnylam is
delivering on a bold vision to turn scientific possibility into
reality, with a robust discovery platform and deep pipeline of
investigational medicines, including three product candidates that
are in late-stage development or will be in 2017. Looking forward,
Alnylam will continue to execute on its "Alnylam 2020" strategy of
building a multi-product, commercial-stage biopharmaceutical
company with a sustainable pipeline of RNAi-based medicines.
Alnylam Forward-Looking StatementsStatements in this
release concerning Alnylam's future expectations, plans and
prospects, including, without limitation, statements about
Alnylam’s proposed public offering, intended use of proceeds and
Alnylam’s expectations regarding future company achievements,
constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform
Act of 1995. Actual results and future plans may differ materially
from those indicated by these forward-looking statements as a
result of various important factors, including, without limitation,
risks related to fluctuations in our stock price, those associated
with market conditions and the satisfaction of customary closing
conditions related to the proposed offering, as well as those risks
more fully discussed in the "Risk Factors" filed with Alnylam's
most recent Quarterly Report on Form 10-Q filed with the SEC and in
other filings that Alnylam makes with the SEC. There can be no
assurance that Alnylam will be able to complete the proposed public
offering on the anticipated terms, or at all. You should not place
undue reliance on these forward-looking statements. In addition,
any forward-looking statements represent Alnylam's views only as of
today and should not be relied upon as representing its views as of
any subsequent date. Alnylam explicitly disclaims any obligation,
except to the extent required by law, to update any forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170524005672/en/
Alnylam Pharmaceuticals, Inc.Christine Regan Lindenboom,
617-682-4340(Investors and Media)orJosh Brodsky,
617-551-8276(Investors)orMichael Mason, 617-551-8327(Investors)
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024